Young Potenza’s Promise Attracts Astellas As Potential Buyer
This article was originally published in PharmAsia News
Astellas has secured an option to acquire the U.S. biotech Potenza as part of a new R&D alliance focusing on immuno-oncology candidates.
You may also be interested in...
New venture DigiTx will give Astellas a leg up in its quest to access novel digital health technologies, in a move unveiled as the Japanese firm reported continued strong growth for top product Xtandi.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.